Literature DB >> 8187435

Scleroderma renal crisis as a possible complication of cyclosporin A withdrawal.

P Casoli1, C Carretti, B Tumiati.   

Abstract

The pharmacological treatment of systemic sclerosis (SSc) has been discouraging. In view of this, therapeutic trials with cyclosporine A (CyA) are outstanding particularly in patients with a rapid cutaneous involvement. We report the case of a patient whose SSc cutaneous manifestations dramatically improved with CyA therapy. Its subsequent withdrawal led to a quick onset of a fatal sclerodermal renal crisis. We believe that in our patient there could have been a cause and effect relationship between the suspension of CyA and kidney sclerodermal complication.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8187435     DOI: 10.1007/bf02229882

Source DB:  PubMed          Journal:  Clin Rheumatol        ISSN: 0770-3198            Impact factor:   2.980


  18 in total

1.  ANTIFIBROTIC THERAPY WITH POTABA.

Authors:  C J ZARAFONETIS
Journal:  Am J Med Sci       Date:  1964-11       Impact factor: 2.378

2.  Skin collagen from scleroderma patients before and after cyclosporin A treatment.

Authors:  C Francès; M C Branchet; O Blétry; C Lefevre; S Boisnic; P Kern; P Godeau
Journal:  Clin Exp Dermatol       Date:  1988-01       Impact factor: 3.470

Review 3.  Epidemiology and natural history of systemic sclerosis.

Authors:  V D Steen; T A Medsger
Journal:  Rheum Dis Clin North Am       Date:  1990-02       Impact factor: 2.670

Review 4.  Graft-versus-host reactions and disease.

Authors:  G W Santos; A D Hess; G B Vogelsang
Journal:  Immunol Rev       Date:  1985-12       Impact factor: 12.988

5.  Penicillamine in systemic sclerosis: a reappraisal.

Authors:  M A Sattar; R T Guindi; T N Sugathan
Journal:  Clin Rheumatol       Date:  1990-12       Impact factor: 2.980

6.  Cyclosporin A treatment of systemic sclerosis.

Authors:  H Zachariae; L Halkier-Sørensen; L Heickendorff; E Zachariae; H E Hansen
Journal:  Br J Dermatol       Date:  1990-05       Impact factor: 9.302

7.  Long-term evaluation of colchicine in the treatment of scleroderma.

Authors:  D Alarcon-Segovia; F Ramos-Niembro; G Ibanez de Kasep; J Alcocer; R P Tamayo
Journal:  J Rheumatol       Date:  1979 Nov-Dec       Impact factor: 4.666

8.  Hypertension and renal failure (scleroderma renal crisis) in progressive systemic sclerosis. Review of a 25-year experience with 68 cases.

Authors:  Y M Traub; A P Shapiro; G P Rodnan; T A Medsger; R H McDonald; V D Steen; T A Osial; S F Tolchin
Journal:  Medicine (Baltimore)       Date:  1983-11       Impact factor: 1.889

9.  Chronic cyclosporine-induced autoimmune disease in the rat: a new experimental model for scleroderma.

Authors:  G M Bos; G D Majoor; R G Willighagen; P J van Breda Vriesman
Journal:  J Invest Dermatol       Date:  1989-11       Impact factor: 8.551

10.  D-Penicillamine therapy in progressive systemic sclerosis (scleroderma): a retrospective analysis.

Authors:  V D Steen; T A Medsger; G P Rodnan
Journal:  Ann Intern Med       Date:  1982-11       Impact factor: 25.391

View more
  3 in total

Review 1.  Combination therapies for systemic sclerosis.

Authors:  C P Denton; C M Black
Journal:  Springer Semin Immunopathol       Date:  2001

2.  An Update on the Treatment of the Cutaneous Manifestations of Systemic Sclerosis: The Dermatologist's Point of View.

Authors:  Magalys Vitiello; Adriana Abuchar; Néstor Santana; Luis Dehesa; Francisco A Kerdel
Journal:  J Clin Aesthet Dermatol       Date:  2012-07

Review 3.  Calcineurin inhibitors in systemic sclerosis - a systematic literature review.

Authors:  Nina N Hofmann; Robert A Ambühl; Suzana Jordan; Oliver Distler
Journal:  Ther Adv Musculoskelet Dis       Date:  2022-05-19       Impact factor: 3.625

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.